Atrys Redeems €25 Million in Bonds and Meets its Corporate Objectives

Atrys Health, a global healthtech company that provides prevention, diagnosis and precision medical treatment, telemedicine and oncology treatment services, has amortized a total of €43 million of debt, after amortizing Mercado Alternativo de Renta Fija (MARF) bonds in the amount of €25 million.

The company has met its corporate objectives communicated to the market in November 2023 : the divestment of 100% of Conversia, the issuance of contingent convertible bonds worth €13.3 million and the amortization of debt for an amount of €43 million.

“Among the debt that the company has amortized, it is worth highlighting the early amortization, carried out on January 5th, for the nominal amount of €25 million of the Bonds issued by Atrys under the Atrys Health International 2020 Fixed Income Program that They were listed on the Marf,” as explained by the company.

Read more about Atrys and find the latest financial news of the day with the Born2Invest mobile app. Don’t waste your time scrolling the internet, our team of seasoned writers will do that for you, so you can stay on top of the market and not miss any important news.

Atrys advances in its purpose of promoting the company’s organic growth in its three strategic areas

After these operations, Atrys advances in its purpose of promoting the company’s organic growth in its three strategic areas , preventive medicine, diagnosis and precision medical treatment, as well as consolidating its geographical positioning, and promoting innovation and the use of Artificial Intelligence as part of its differentiating value proposition.

According to Santiago de Torres, executive president of Atrys, “2023 has been a year of organic growth in which we have demonstrated that Atrys is a robust business with strong growth: with these operations, we strengthen the company’s financial structure and boost our leadership in the sector.”

Atrys achieved a turnover of €169.5 million in the first nine months of the year, which represented a growth of 26.2% compared to the same period of the previous year. The adjusted gross operating result (ebitda) rose to €31.8 million, 46.1% more  than in the same period of 2022.

__

(Featured image by Letti-S via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us